FDA QUALITY INITIATIVE TWO-YEAR ANNIVERSARY
This article was originally published in The Gold Sheet
...marks a shift in focus from assessment and design to implementation. With the conceptual framework in place, FDA and industry are now turning their attention to putting principles into practice. In late September, FDA released a detailed report and a bolus of related documents intended to drive the initiative forward. Among the significant GMP-related issues addressed in the documents are: • innovation and continuous improvement • risk-based inspections • warning letter assessment • Part 11 • the pharmaceutical inspectorate curriculum • quality system implementation • GMP harmonization • process analytical technology • aseptic processing • combination product GMPs, and • clinical trial computer systems. [A discussion by CDER Office of Compliance Director David Horowitz of the initiative’s progress and future direction is included].
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.